24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01989468
Recruitment Status : Completed
First Posted : November 21, 2013
Last Update Posted : July 13, 2018
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 28, 2018
  Actual Study Completion Date : March 28, 2018